For Geron Corporation GERN, 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo ...

This data feed is not available at this time.

Research reports are not currently available for GERN.

In this article, we are going to take a look at where Geron Corp. (NASDAQ:GERN) stands against the other stocks. Ten companies kicked off this week's trading mirroring a decline on Dow Jones with ...

After hours: 7:54:20 pm GMT-5 ...

Faisal Khurshid, an analyst from Leerink Partners, maintained the Buy rating on Geron (GERN – Research Report). The associated price target remains the same with $7.00. Discover outperforming ...

Geron (GERN) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the approval of Rytelo for the treatment of ...

After hours: 8 January at 19:49:33 GMT-5 ...

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.